Free Trial

TherapeuticsMD (TXMD) Competitors

TherapeuticsMD logo
$1.18 -0.02 (-1.67%)
Closing price 07/11/2025 03:53 PM Eastern
Extended Trading
$1.20 +0.02 (+1.69%)
As of 07/11/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TXMD vs. AVTX, IPA, RENB, KLRS, BLUE, ADVM, VRCA, DTIL, AADI, and ATRA

Should you be buying TherapeuticsMD stock or one of its competitors? The main competitors of TherapeuticsMD include Avalo Therapeutics (AVTX), ImmunoPrecise Antibodies (IPA), Renovaro (RENB), Kalaris Therapeutics (KLRS), bluebird bio (BLUE), Adverum Biotechnologies (ADVM), Verrica Pharmaceuticals (VRCA), Precision BioSciences (DTIL), Aadi Bioscience (AADI), and Atara Biotherapeutics (ATRA). These companies are all part of the "pharmaceutical products" industry.

TherapeuticsMD vs. Its Competitors

Avalo Therapeutics (NASDAQ:AVTX) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Avalo Therapeutics has a net margin of 0.00% compared to TherapeuticsMD's net margin of -114.07%. Avalo Therapeutics' return on equity of 111.00% beat TherapeuticsMD's return on equity.

Company Net Margins Return on Equity Return on Assets
Avalo TherapeuticsN/A 111.00% 58.88%
TherapeuticsMD -114.07%-7.86%-5.46%

In the previous week, Avalo Therapeutics had 2 more articles in the media than TherapeuticsMD. MarketBeat recorded 3 mentions for Avalo Therapeutics and 1 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 1.87 beat Avalo Therapeutics' score of 0.94 indicating that TherapeuticsMD is being referred to more favorably in the news media.

Company Overall Sentiment
Avalo Therapeutics Positive
TherapeuticsMD Very Positive

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 3.0% of Avalo Therapeutics shares are held by company insiders. Comparatively, 2.3% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

TherapeuticsMD has higher revenue and earnings than Avalo Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avalo Therapeutics$440K117.65-$35.13MN/AN/A
TherapeuticsMD$1.76M7.76-$2.18MN/AN/A

Avalo Therapeutics has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.

Avalo Therapeutics currently has a consensus target price of $30.00, suggesting a potential upside of 527.62%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Avalo Therapeutics is more favorable than TherapeuticsMD.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avalo Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
TherapeuticsMD
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Avalo Therapeutics beats TherapeuticsMD on 11 of the 14 factors compared between the two stocks.

Get TherapeuticsMD News Delivered to You Automatically

Sign up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TXMD vs. The Competition

MetricTherapeuticsMDMED IndustryMedical SectorNASDAQ Exchange
Market Cap$13.89M$2.74B$5.62B$9.10B
Dividend YieldN/A1.79%5.24%4.00%
P/E RatioN/A9.4228.1020.27
Price / Sales7.76714.14429.7098.72
Price / CashN/A165.3637.4658.16
Price / Book0.504.608.045.49
Net Income-$2.18M$31.26M$3.18B$250.45M
7 Day Performance5.36%4.80%3.62%4.78%
1 Month Performance-1.67%5.42%4.05%7.67%
1 Year Performance-36.22%-4.36%30.00%16.43%

TherapeuticsMD Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TXMD
TherapeuticsMD
0.8644 of 5 stars
$1.18
-1.7%
N/A-33.7%$13.89M$1.76M0.00420Positive News
AVTX
Avalo Therapeutics
3.0147 of 5 stars
$4.99
+4.4%
$30.00
+501.2%
-60.2%$51.76M$440K0.0040News Coverage
IPA
ImmunoPrecise Antibodies
3.099 of 5 stars
$1.06
-4.5%
$4.00
+277.4%
+54.4%$50.80M$18.16M-0.9180Positive News
Upcoming Earnings
Gap Down
RENB
Renovaro
1.9337 of 5 stars
$0.29
-1.3%
N/A-81.4%$50.38MN/A-0.3820News Coverage
KLRS
Kalaris Therapeutics
N/A$2.67
+1.9%
N/AN/A$49MN/A0.00110
BLUE
bluebird bio
1.5832 of 5 stars
$4.97
flat
$44.60
+797.4%
N/A$48.67M$103.95M-0.13520
ADVM
Adverum Biotechnologies
4.582 of 5 stars
$2.15
-7.3%
$23.80
+1,007.0%
-67.4%$48.47M$1M-0.34190Positive News
VRCA
Verrica Pharmaceuticals
4.5079 of 5 stars
$0.53
+1.4%
$8.00
+1,409.1%
-90.5%$48.34M$7.57M-0.4440News Coverage
Gap Down
DTIL
Precision BioSciences
4.2789 of 5 stars
$4.20
-2.3%
$47.00
+1,019.0%
-54.6%$47.68M$68.70M-2.09200Gap Down
AADI
Aadi Bioscience
0.4713 of 5 stars
$1.93
+1.6%
$1.67
-13.6%
+31.3%$47.67M$25.07M-0.8540
ATRA
Atara Biotherapeutics
4.5506 of 5 stars
$7.72
-3.0%
$17.75
+129.9%
-9.1%$47.45M$128.94M-2.08330Positive News

Related Companies and Tools


This page (NASDAQ:TXMD) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners